Image and copyright: BioNTech.
Yesterday, Ugur Sahin, CEO of BioNTech, gave an insight into the company’s upcoming plans at a healthcare conference. The Mainz-based company is expecting Comirnaty sales of EUR 13 billion to EUR 17 billion in the current year. In 2021, the vaccine is expected to have contributed between 16 billion euros and 17 billion euros to sales.
Together with Pfizer, the group is currently working on a vaccine against shingles. We are also still active in oncology and the flu.
Goldman Sachs analysts are responding to these developments. They confirm the “neutral” rating for BioNTech shares. The price target for the title was previously $ 289.00. It rises to $ 299.00 in the new study.
BioNTech shares gain 1.0 percent to 191.90 euros in the evening on Tradegate. On the Nasdaq, the paper increased 2.0 percent to $ 220.13.
For the share snapshot – BioNTech: click here!
Read more about BioNTech in the report from January 11th, 2022
BioNTech: 2022 will be a year with many plans – also outside of Comirnaty
BioNTech expects sales of the COVID-19 vaccine Comirnaty between EUR 13 billion and EUR 17 billion in 2022. This is what BioNTech CEO Ugur Sahin said at the JP Morgan Healthcare Conference on Tuesday. For the year 2021, which came to an end, the Mainz-based company had forecast corporate sales of between 16 billion euros and 17 billion euros. The biotech company expects new contracts for the COVID-19 vaccine this year. There are capacities for 4 billion cans and purchase agreements for 2 billion cans exist. BioNTech, like its partner Pfizer, assumes that – subject to regulatory approval – a version of Comirnaty adapted to the Omikron variant may be available in March. A clinical study with the adapted vaccine is scheduled to start at the end of January. In 2022, a series of further clinical studies in other indications in the vaccine sector of the biotech company … read more!
4investors-News – BioNTech
DGAP-News of this company
Master data of this security: WKN / ISIN, stock exchange etc.